[1] Common side effects include muscle and joint pains, fever, loss of appetite, and headache.

[5] The combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance.

[8] In 2001, the first fixed dose artemisinin-based combination therapy to meet the World Health Organization's (WHO) pre-qualification criteria for efficacy, safety and quality was created.

[citation needed] Novartis and its partners invested heavily in expanding production capacity at their facilities in China, and Suffern, New York.

In April 2008, Novartis further reduced the public sector price of Coartem by approximately 20%, to an average of US$0.80 (or US$0.37 for a child's treatment pack).

Prior to this program, Novartis was criticised for a court case they launched against India, seeking to prohibit the marketing of cheap generic drugs.

An Indian court ruled against Novartis, saying that the case was a "threat to people suffering from cancer [...] and other diseases who are too poor to pay for them".